NCT00557622View on ClinicalTrials.gov

Clinical Evaluation of BRL29060A (Paroxetine Hydrochloride Hydrate) in Posttraumatic Stress Disorder (PTSD)

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

January 25, 2008

Primary Completion Date

December 11, 2008

Study Completion Date

December 11, 2008

Conditions
Post-Traumatic Stress DisorderStress Disorders, Post-Traumatic
Interventions
DRUG

paroxetine

BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD)

OTHER

placebo

placebo

Trial Locations (9)

272-0133

GSK Investigational Site, Chiba

272-01

GSK Investigational Site, Chiba

113-8603

GSK Investigational Site, Tokyo

113-86

GSK Investigational Site, Tokyo

114-0002

GSK Investigational Site, Tokyo

114-00

GSK Investigational Site, Tokyo

162-0056

GSK Investigational Site, Tokyo

162-8666

GSK Investigational Site, Tokyo

170-0002

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY